ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • back pain and outcome measures
  • back pain and patient outcomes
  • back pain and population studies
  • back pain and posture
  • Back pain and psoriatic arthritis
  • back pain and quality of life
  • Back pain and spondylarthritis
  • back pain and spondylarthropathy
  • Back pain and systemic lupus erythematosus (SLE)
  • Back pain and ultrasound
  • Back surgery
  • back surgery and healthcare reform
  • Bacterial infections
  • bacterial infections and infection
  • bacterial infections and oral
  • bacterial infections and rheumatoid arthritis (RA)
  • Bacterial infections and systemic lupus erythematosus (SLE)
  • bacterial infections and uveitis
  • bacterial infections and vasculitis
  • BAFF
  • BAFF and arthritis
  • BAFF and cytokines
  • BAFF and IL-6
  • BAFF and lymphocytes
  • BAFF and pregnancy
  • BAFF and rheumatoid arthritis (RA)
  • BAFF and Sjogren's syndrome
  • BAFF and SLE
  • BAFF and systemic lupus erythematosus (SLE)
  • bariatric and biomarkers
  • bariatric and psoriatic arthritis
  • Bariatric Surgery
  • baricitinib
  • barriers
  • baseline kidney biopsy
  • basic calcium phosphate
  • basic research
  • basic research and autoimmunity
  • Basic research and rheumatoid arthritis (RA)
  • Basic Science
  • Basic Science and B cells
  • Basic Science and systemic lupus erythematosus (SLE)
  • BDCAF
  • bDMARDs
  • Behçet's Syndrome
  • Behavioral strategies
  • Behavioral strategies and osteoarthritis
  • Behavioral strategies and rheumatoid arthritis (RA)
  • Behcet's disease
  • Behcet's syndrome
  • Behçet's Syndrome
  • Behcet's syndrome and adipocytokines
  • Behcet's syndrome and amyloidosis
  • Behcet's syndrome and autoantibodies
  • Behcet's syndrome and chemokines
  • Behcet's syndrome and Clinical
  • Behcet's syndrome and cluster analysis
  • Behcet's syndrome and Disease Activity
  • Behcet's syndrome and familial Mediterranean fever
  • Behcet's syndrome and functions
  • Behcet's syndrome and genetics
  • Behcet's syndrome and genomics
  • Behcet's syndrome and infliximab
  • Behcet's syndrome and interleukins (IL)
  • Behcet's syndrome and KIR (Killer Ig like receptor)
  • Behcet's syndrome and macrophage
  • Behcet's syndrome and medication
  • Behcet's syndrome and metabolomics
  • Behcet's syndrome and microbiome
  • Behcet's syndrome and outcome measures
  • Behcet's syndrome and outcomes
  • Behcet's syndrome and patient questionnaires
  • Behcet's syndrome and pediatric rheumatology
  • Behcet's syndrome and polymorphism
  • Behcet's syndrome and proteomics
  • Behcet's syndrome and quality of life
  • Behcet's syndrome and Redox Balance
  • Behcet's syndrome and spondylarthropathy
  • Behcet's syndrome and thrombosis
  • Behcet's syndrome and tocilizumab
  • Behcet's syndrome and treatment
  • Behcet's syndrome and uveitis
  • Behcet's syndrome and vaccines
  • Behcet's syndrome and vasculitis
  • Behcet's syndrome and Work Disability
  • beliefs and adherence
  • belimumab
  • belimumab and B cell targeting
  • belimumab and clinical trials
  • Belimumab and corticosteroids
  • belimumab and flow cytometry
  • belimumab and health disparities
  • belimumab and immunoglobulin (IG)
  • belimumab and juvenile SLE
  • belimumab and meta-analysis
  • belimumab and outcomes
  • belimumab and pharmacokinetics
  • belimumab and steroids
  • belimumab and synovial cells
  • belimumab and systemic lupus erythematosus (SLE)
  • belimumab and treatment
  • belimumab and vaccines
  • Benchmarking tools
  • benchmarking tools and Knee
  • Benefits
  • benzodiazepines and adults
  • Best Practice
  • Best practices
  • best practices and social work
  • beta-2 glycoprotein I
  • beta-endorphin and neurotensin
  • Bias and rheumatic disease
  • Big data
  • big data and antibodies
  • big data and data analysis
  • big data and death
  • big data and diagnosis
  • big data and diagnostic criteria
  • big data and epidemiologic methods
  • big data and health care cost
  • big data and neutrophils
  • big data and quality of life
  • big data and safety
  • big data and salivary gland
  • BILAG
  • bile and hepatic disorders
  • Billing
  • Bio-naïve Active Psoriatic Arthritis and Skin and Nail Psoriasis
  • bioequivalence
  • bioinformatic and Gene siganture
  • Bioinformatics
  • bioinformatics and autoimmunity
  • bioinformatics and Basic Science
  • bioinformatics and biomarkers
  • bioinformatics and diagnosis
  • bioinformatics and Electronic Health Record
  • bioinformatics and interferons
  • bioinformatics and networking
  • bioinformatics and pathogenesis
  • bioinformatics and population studies
  • bioinformatics and rheumatoid arthritis (RA)
  • bioinformatics and steroids
  • biologic
  • Biologic agents
  • Biologic agents and adherence
  • Biologic agents and adverse events
  • Biologic agents and ankylosing spondylitis (AS)
  • Biologic agents and axial spondyloarthritis
  • Biologic agents and biomarkers
  • Biologic agents and biosimilars
  • Biologic agents and chikungunya
  • Biologic agents and Churg-Strauss syndrome
  • Biologic agents and Clinical Response
  • Biologic agents and clinical trials
  • Biologic agents and computed tomography (CT)
  • Biologic agents and Disease Activity
  • Biologic agents and disease-modifying antirheumatic drugs
  • Biologic agents and inflammation
  • Biologic agents and Janus kinase (JAK)
  • Biologic agents and lipids
  • Biologic agents and NONI
  • Biologic agents and observation
  • Biologic agents and patient questionnaires
  • Biologic agents and prognosis
  • Biologic agents and PROM
  • Biologic agents and psoriatic arthritis
  • Biologic agents and pulmonary complications
  • Biologic agents and remission
  • Biologic agents and rheumatoid arthritis
  • Biologic agents and rheumatoid arthritis (RA)
  • Biologic agents and spondylarthritis
  • Biologic agents and statins
  • Biologic agents and systemic vasculitides
  • Biologic agents and treatment
  • Biologic agents and tuberculosis
  • Biologic agents and uveitis
  • Biologic DMARDs
  • Biologic drugs
  • biologic drugs and biologic response modifiers
  • biologic drugs and certolizumab pegol
  • biologic drugs and clinical practice
  • biologic drugs and clinical trials
  • biologic drugs and drug toxicity
  • biologic drugs and fever
  • biologic drugs and funding
  • Biologic drugs and hepatitis
  • biologic drugs and immune response
  • biologic drugs and inflammatory arthritis
  • biologic drugs and injection fear
  • Biologic drugs and juvenile idiopathic arthritis (JIA)
  • biologic drugs and liver chemistry
  • biologic drugs and longitudinal studies
  • biologic drugs and lupus nephritis
  • biologic drugs and patient preferences
  • biologic drugs and pediatric rheumatology
  • Biologic drugs and psoriatic arthritis
  • Biologic drugs and quality of life
  • biologic drugs and randomized trials
  • biologic drugs and registries
  • Biologic drugs and rheumatoid arthritis
  • First |
  • « Previous Page
  • 3
  • 4
  • 5
  • 6
  • 7
  • [8]
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology